Healthcare UK | Pharma Times | 31 August 2017

High hopes for funding low-priority drug trials

It's no secret that big pharma invests billions in R&D each year, despite recent headlines bemoaning the cuts companies have made to their research budgets in recent years. This investment in exploratory-stage compounds has resulted in a robust pipeline of promising new therapies across a number of disease areas, which could save and improve millions of lives the world over. However, how many of these potential new drugs are being shelved indefinitely because of a lack of resources to fund costly and time-intensive clinical trials? In this article, Ben van der Schaaf at Arthur D. Little, discusses that although not every pipeline drug can get blockbuster funding, there are ways to breathe new life into neglected products.

Healthcare UK | European Pharmaceutical Manufacturer | 30 August 2017

A model fund

Today's clinical trial costs can cost biopharma companies upwards of $100mn before they even begin to consider additional investment in the marketing and distribution mechanisms that will deliver new life enhancing therapies to patients. For those major drug companies that spent the last decade building a robust pipeline of early stage compounds and indications, these sky-high development costs mean they have a wide portfolio of potential assets without the resources to get them through trial phase. The result? Pharmaceutical businesses with strong R&D pipelines are losing billions each year in potential revenue while promising new therapies sit dormant, waiting for their patents to expire. In this article, Ben van der Schaaf at Arthur D. Little, gives a five-step guide to explore possible funding partnerships for lower-priority drug trials - a new model for big pharma.

Healthcare | The Pharma Letter | 17 May 2017

Partnering to address the rising cost of clinical trials

The cost of the clinical trial process today is upwards of $100mn. So how can drug developers with robust R&D pipelines but a limited operating budget make the most of their portfolios and get as many promising new therapies to market in the narrow window before patents expire? In a word, partnerships. In this article, Ben van der Schaaf at Arthur D. Little discusses why by working with CROs, universities, and patient advocacy organizations, innovative drug makers can find investors who see their intellectual property as a valuable starting point for the drug development process.

Healthcare | Pharmaphorum | 15 May 2017

New funding models to progress low-priority clinical trials

The cost of funding a clinical trial today can run biopharma companies upwards of $100mn, and that does not even begin to consider the costs of marketing and distribution necessary for a new life enhancing therapy to reach patients' hands. Global pharma businesses that spent the last decade building a robust pipeline of early stage compounds and indications are now faced with a wide portfolio of potential assets without the resources to fund their development. The result? Drug makers who've made the investments necessary to ensure a strong R&D pipelines are now losing billions each year in potential revenue as promising new therapies are sitting dormant, waiting for their patent to expire. In this article, Ben van der Schaaf at Arthur D. Little discusses new funding models to progress low-priority clinical trials.

Healthcare | Infrastructure Intelligence | 15 November 2016

Is the car industry about to change for good?

In its "Global Automotive Mobility Study", experts from Arthur D. Little shed light on the three megatrends of autonomous driving: electric mobility and car sharing.

Healthcare | International Journal of Healthcare Management | 13 November 2016

Embracing digital health in the Pharmaceutical Industry

Disruptive innovations challenge pharma companies to change up business models and value chains to stay ahead. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how as the industry becomes more digitalized, pharma companies will need to implement changes that will ultimately lead to new business models and value chains.

Healthcare | European Biopharmaceutical Review | 15 July 2016

From the Outside

Innovation from sources outside of the traditional healthcare system is changing the pharma industry. A digital revolution in many business models means a positive overall change for patient care - but introducing new services too quickly could see development in other areas suffering. In this article Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz from Arthur D. little discuss the impact of digital health on the pharmaceutical industry.

Healthcare | International Pharmaceutical Industry | 01 June 2016

Digital health: increasing the quality and efficiency of care

It is becoming clear that in order to stay relevant in the future healthcare ecosystem, pharma companies must look to business models that foster much more direct patient engagement than previously. New methods offer significant potential in increasing the quality and efficiency of care. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz from Arthur D. Little explain how digital health solutions can solve the major long-term issues of pharma’s most important client groups – patients, providers and payers – all at the same time.

Healthcare | Drug Discovery World | 01 May 2016

Digital pharma – responding to challenges and opportunities from outside

Innovation has always been one of the foundations for success in the pharmaceutical industry. While the sector has been very good at developing innovation from scratch or incremental innovation of existing products, it now faces an ultimately differently challenge - dealing with disruptive innovation that is driven by inventions outside the healthcare sector. New players from the digital arena are currently redefining the way the industry works. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how digital is reshaping the pharma arena.

Healthcare | Healthcare Market News | 01 May 2016

Transforming the value chain with digital health

The business model of the pharmaceutical industry is being transformed by digital health. It will significantly extend current business models, or even create completely new ones for the industry. In order to implement innovative solutions ahead of new entrants, pharma companies will need to undergo major transformation programs and convert three completely different value chains: pharma, medical devices for measuring health parameters, and IT solutions to process and connect data. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how pharma companies can get ahead of disruptive innovations and thrive in the digital world.

Search by keyword

In the press (44 Results)

Browse by article

Browse by publication date

| |Bookmark Arthur D. Little